Monthly Archives: February 2019

• 

ASCO GU 2019: Questions and lessons moving forward from CARMENA: A medical oncologist’s perspective

By Sharon Kell|2019-02-28T11:05:40+00:0028 Feb 2019|Surgery|

The following paper was presented at the American Society for [...]

Read More

Comments Off on ASCO GU 2019: Questions and lessons moving forward from CARMENA: A medical oncologist’s perspective

• 

New cancer drug payment system could speed up access to treatments

By Sharon Kell|2019-02-27T14:30:10+00:0027 Feb 2019|Drug treatments|

Cancer Research UK and the Greater Manchester Health and Social [...]

Read More

Comments Off on New cancer drug payment system could speed up access to treatments

• 

Sources of frustration for patients with kidney cancer

By Sharon Kell|2019-02-27T14:01:11+00:0027 Feb 2019|Uncategorized|

This observation study involved 450 patients with renal cell carcinoma [...]

Read More

Comments Off on Sources of frustration for patients with kidney cancer

• 

ASCO GU 2019: Interviews with the experts

By Sharon Kell|2019-02-27T13:36:28+00:0027 Feb 2019|Drug treatments|

The following interviews with kidney cancer experts were recorded by [...]

Read More

Comments Off on ASCO GU 2019: Interviews with the experts

• 

ASCO GU 2019: Nivolumab-ipilimumab survival benefit in advanced kidney cancer

By Sharon Kell|2019-02-27T12:11:24+00:0027 Feb 2019|Drug treatments|

New 30-month survival data from the CheckMate 214 study were [...]

Read More

Comments Off on ASCO GU 2019: Nivolumab-ipilimumab survival benefit in advanced kidney cancer

• 

ASCO GU 2019: Early tumour shrinkage and improved survival with cabozantinib

By Sharon Kell|2019-02-27T11:21:21+00:0027 Feb 2019|Drug treatments|

The results from the following study were presented at the [...]

Read More

Comments Off on ASCO GU 2019: Early tumour shrinkage and improved survival with cabozantinib

• 

ASCO GU 2019: Avelumab plus axitinib combination superior to sunitinib

By Sharon Kell|2019-02-27T11:11:31+00:0027 Feb 2019|Drug treatments|

The results from the following study were presented at the [...]

Read More

Comments Off on ASCO GU 2019: Avelumab plus axitinib combination superior to sunitinib

• 

ASCO GU 2019: Nivolumab monotherapy for non-clear cell renal cell carcinoma

By Sharon Kell|2019-02-26T15:53:03+00:0026 Feb 2019|Drug treatments|

The results from the following study were presented at the [...]

Read More

Comments Off on ASCO GU 2019: Nivolumab monotherapy for non-clear cell renal cell carcinoma

• 

ASCO GU 2019: Tivozanib effective for refractory metastatic kidney cancer

By Sharon Kell|2019-02-26T13:20:25+00:0026 Feb 2019|Drug treatments|

The results from the following study were presented at the [...]

Read More

Comments Off on ASCO GU 2019: Tivozanib effective for refractory metastatic kidney cancer

• 

ASCO GU 2019: Patient perspectives on cytoreductive nephrectomy after CARMENA

By Sharon Kell|2019-02-26T12:59:31+00:0026 Feb 2019|Surgery|

The following survey assessed patient views related to cytoreductive nephrectomy [...]

Read More

Comments Off on ASCO GU 2019: Patient perspectives on cytoreductive nephrectomy after CARMENA